Graf Akcie AKBA (Akebia Therapeutics Inc.). Diskuze k akciím AKBA. Aktuální informace AKBA.

Základní informace o společnosti Akebia Therapeutics Inc. (Akcie AKBA)

Skvělé pro velmi rychlou analýzu společnosti. Investor může porovnat různé ukazatele s konkurenčními firmami.

Tržní kapitalizace 467.54M
Hodnota podniku (EV) N/A
Tržby 221.904M
EBITDA N/A
Zisk -299.58
Růst v tržbách Q/Q -41.30 %
Růst v tržbách Y/Y -34.76 %
P/E (Cena vůči ziskům) 0.00
Forward P/E -9.94
EV/Sales 1.73
EV/EBITDA N/A
EV/EBIT N/A
PEG N/A
Price/Sales 2.12
P/FCF N/A
Price/Book 1.90
Účetní hodnota na akcii 1.54
Hotovost na akcii 1.67
FCF vůči ceně -40.84 %
Počet zaměstnanců 380
Tržba na zaměstnance 583.958k
Profit margin -129.85 %
Operating margin -129.68 %
Gross margin -0.20 %
EBIT margin -128.53 %
EBITDA margin -81.08 %
EPS - Zisk na akcii N/A
EPS - Kvartální růst -60.16 %
EPS - Očekávaný růst příští rok -21.43 %
Return on assets -46.79 %
Return on equity -125.60 %
ROIC -52.93 %
ROCE -63.91 %
Dluhy/Equity 1.60
Čistý dluh/EBITDA 1.68
Current ratio 2.00
Quick Ratio 1.77
Volatilita 4.63
Beta 1.48
RSI 53.83
Cílová cena analytiků 7
Známka akcie (dle analytiků) 1.75
Insider ownership 1.14 %
Institutional ownership 66.65 %
Počet akcií 174.537M
Procento shortovaných akcií 11.83 %
Short ratio 5.52 %
Dividenda N/A
Procentuální dividenda N/A %
Dividenda/Zisk N/A %
Obchodovaná od 2014
Země United States

Finanční výsledky akcie AKBA

Finanční výsledky společnosti, napoví investorovi, zda se jedná o kvalitní společnost.

# 2020 2019 2018 2017 2016 2015
Revenue$335.001$207.742$181.227$1.535----
Cost Of Goods Sold$145.336$7.768------
Gross Profit$189.665$199.974$181.227$1.535----
Research And Development Expenses$322.969$291.007$230.893$115.785$43.016$23.263$8.902$5.632
SG&A Expenses$149.455$87.061$27.008$22.21$18.497$14.677$7.031$2.891
Other Operating Income Or Expenses$-3.529$-0.067------
Operating Expenses$621.289$385.903$257.901$137.995$61.513$37.94$15.933$8.523
Operating Income$-286.288$-178.161$-76.674$-136.46$-61.513$-37.94$-15.933$-8.523
Total Non-Operating Income/Expense$-0.002$6.235$3.003$0.713$0.797$0.906$2.766$0.327
Pre-Tax Income$-286.29$-171.926$-73.671$-135.747$-60.716$-37.034$-13.167$-8.196
Income Taxes$-6.631$-28.338------
Income After Taxes$-279.659$-143.588$-73.671$-135.747$-60.716$-37.034$-13.167$-8.196
Other Income--------
Income From Continuous Operations$-279.659$-143.588$-73.671$-135.747$-60.716$-37.034$-13.167$-8.196
Income From Discontinued Operations--------
Net Income$-279.659$-143.588$-73.671$-135.747$-60.716$-123.933$-69.053$-11.519
EBITDA$-248.461$-176.972$-75.447$-135.67$-60.859$-37.623$-15.172$-6.852
EBIT$-286.288$-178.161$-76.674$-136.46$-61.513$-37.94$-15.933$-8.523
Basic Shares Outstanding118584438261510
Shares Outstanding118584438261510
Basic EPS$-2.36$-2.47$-1.69$-3.60$-2.29$-8.04$-126.94$-27.82
EPS - Earnings Per Share$-2.36$-2.47$-1.69$-3.60$-2.29$-8.04$-126.94$-27.82
# 2020 2019 2018 2017 2016 2015
Current Ratio1.48731.76252.53962.593211.882116.0465
Long-term Debt / Capital0.1611-----
Debt/Equity Ratio0.1920.0236----
Gross Margin56.616396.2607100100--
Operating Margin-85.4589-85.7607-42.3083-8889.901--
EBIT Margin-85.4589-85.7607-42.3083-8889.901--
EBITDA Margin-74.1672-85.1884-41.6312-8838.437--
Pre-Tax Profit Margin-85.4595-82.7594-40.6512-8843.452--
Net Profit Margin-83.4801-69.1184-40.6512-8843.452--
Asset Turnover0.43440.20850.49750.0051--
Inventory Turnover Ratio1.24910.068----
Receiveable Turnover8.56580.88915.29660.0454--
Days Sales In Receivables42.6112410.541168.91278042.603--
ROE - Return On Equity-70.8433-22.5793-60.1033-199.2762-46.3488-35.5829
Return On Tangible Equity-576.7119-56.8166-60.1033-199.2762-46.3488-35.5829
ROA - Return On Assets-36.2628-14.4087-20.2256-45.2164-42.4766-33.3655
ROI - Return On Investment-59.4309-22.5793-60.1033-199.2763-46.3488-35.5829
Book Value Per Share3.24445.44052.57441.7644.27235.1091
Operating Cash Flow Per Share-0.4946-0.3888-2.82633.5152-0.19619.047
Free Cash Flow Per Share-0.5231-0.3792-2.7933.4603-0.196819.067